Chemomab Therapeutics Ltd
CMMB1.530USD
+0.080+5.52%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
37.68MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Chemomab Therapeutics Ltd Unternehmen
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd Informationen
BörsenkürzelCMMB
Name des UnternehmensChemomab Therapeutics Ltd
IPO-datumAug 14, 2012
CEOMor (Adi)
Anzahl der mitarbeiter16
WertpapierartDepository Receipt
GeschäftsjahresendeAug 14
AddresseKiryat Atidim, Building 7
StadtTEL AVIV-YAFO
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl6158002
Telefon972773310156
Websitehttps://www.chemomab.com/
BörsenkürzelCMMB
IPO-datumAug 14, 2012
CEOMor (Adi)
Führungskräfte von Chemomab Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-3112.00%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-3112.00%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
Andere
79.66%
Aktionäre
Aktionäre
Anteil
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
Andere
79.66%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
9.55%
Family Office
4.60%
Corporation
4.50%
Hedge Fund
3.78%
Research Firm
1.91%
Investment Advisor
1.03%
Investment Advisor/Hedge Fund
0.53%
Andere
74.10%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
30
390.31K
17.98%
--
2025Q3
30
390.31K
17.98%
-667.39K
2025Q2
30
1.06M
18.61%
+124.78K
2025Q1
31
932.92K
24.29%
-212.50K
2024Q4
32
1.04M
26.27%
-97.26K
2024Q3
29
1.14M
22.64%
+165.56K
2024Q2
28
668.24K
21.48%
+2.79K
2024Q1
32
666.14K
22.68%
-139.12K
2023Q4
33
705.36K
20.90%
+69.50K
2023Q3
33
635.85K
25.86%
-196.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Otto (Erik)
422.50K
6.86%
+133.75K
+46.32%
Aug 11, 2025
Apeiron Investment Group Ltd
283.00K
4.6%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
4.5%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
179.43K
2.92%
-5.09K
-2.76%
Sep 30, 2025
Morgan Stanley & Co. LLC
90.06K
1.46%
-313.47K
-77.68%
Sep 30, 2025
Mor George (Adi)
79.27K
1.29%
--
--
Dec 31, 2024
Ikarian Capital LLC
53.26K
0.87%
-1.00
-0.00%
Sep 30, 2025
George (Kobi)
50.06K
0.81%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.57%
-2.50K
-6.61%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
